| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2012 | US8124729 Splice variants of human G-protein coupled receptor HGPRBMY29 (HGPRMBY29SV2) |
| 02/28/2012 | US8124728 CA125 gene and its use for diagnostic and therapeutic interventions |
| 02/28/2012 | US8124725 PDGF-Rβ binders |
| 02/28/2012 | US8124724 Peptides and related molecules that modulate nerve growth factor activity |
| 02/28/2012 | US8124723 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 02/28/2012 | US8124722 Soluble CD14 antigen |
| 02/28/2012 | US8124650 Antitumor combinations containing taxane derivatives and epidophyllotoxins |
| 02/28/2012 | US8124590 Biodegradable immunomodulatory formulations and methods for use thereof |
| 02/28/2012 | US8124588 Chimeric plasminogen activators and their pharmaceutical use |
| 02/28/2012 | US8124587 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa |
| 02/28/2012 | US8124586 Prevention and reduction of blood loss |
| 02/28/2012 | US8124585 Composition for relieving discomfort |
| 02/28/2012 | US8124584 Macrocyclic hepatitis C serine protease inhibitors |
| 02/28/2012 | US8124583 Composition and method for self-assembly and mineralization of peptide-amphiphiles |
| 02/28/2012 | US8124582 Treatment of diabetes |
| 02/28/2012 | US8124581 Methods for treating breast cancer using NRIF3 related molecules |
| 02/28/2012 | US8124580 Apolipoprotein A1 mimetics and uses thereof |
| 02/28/2012 | US8124579 inhibiting smooth muscle cell proliferation and/or migration; smooth muscle relaxation; increasing the contractile rate in heart muscle; promoting wound healing; reducing scar formation; disrupting focal adhesions; regulating actin polymerization; host cell; biomedical device |
| 02/28/2012 | US8124405 Fusion proteins |
| 02/28/2012 | US8124393 Compositions and methods for inducing or inhibiting activities of selected human cells |
| 02/28/2012 | US8124378 Murine zcytor17 ligand polynucleotides |
| 02/28/2012 | US8124356 Methods of purifying zsig33 |
| 02/28/2012 | US8124130 Formulations and methods for recovery from dental surgery |
| 02/28/2012 | US8124099 Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| 02/28/2012 | US8124097 Antiinflammatory agents; binding proteins, encoding polynucleotides and vectors; having decay accelerating and cofactor activity |
| 02/28/2012 | US8124095 Fusion proteins for delivery of erythropoietin to the CNS |
| 02/28/2012 | US8124084 Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra |
| 02/28/2012 | US8124081 Using amyloid A specific immunoglobulin for use in prevention and treatment of infection, nervous system, cell proliferative and inflammatory disorders |
| 02/28/2012 | US8124077 Anti-IL-TIF antibodies and methods of making |
| 02/28/2012 | US8124075 treating a human spinal disc with defect by injecting into the disc a mixture comprises supplement drug and autologous fibrinogen and a snake venom to change fibrinogen to fibrin biosealants |
| 02/28/2012 | US8124074 Fusion proteins |
| 02/28/2012 | US8124073 Targeting of glycoprotein therapeutics |
| 02/28/2012 | US8124072 sufficient quantity of limonene suitable to solubilize said coenzyme Q-10 and carnitine; and an acceptable carrier |
| 02/28/2012 | US8124071 Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells |
| 02/28/2012 | US8124066 Methods of using interleukin-2 mutants with reduced toxicity |
| 02/28/2012 | US8124065 Cytokine Protein Family |
| 02/28/2012 | US8124057 Propellant-based nanoparticulate dry powder aerosols and method of making |
| 02/28/2012 | US8124052 for drug screening antitumor angents; genetic engineering; microarrays; kits |
| 02/28/2012 | US8124051 Peptide, oligonucleotide suppressor of antiapoptotic cellular defense and anti-tumor agent covalently attached to same carrier peptide via bi-functional water-soluble polymer, so there is simultaneous uptake of suppressor and anti-tumor agent by tumor cells |
| 02/28/2012 | US8123707 Method and apparatus for connective tissue treatment |
| 02/28/2012 | CA2500215C Nucleic acid coated particles |
| 02/28/2012 | CA2490622C Milk protein isolate and method for preparing same |
| 02/28/2012 | CA2485506C A method for in vitro molecular evolution of protein function |
| 02/28/2012 | CA2392202C Constructs for delivery of therapeutic agents to neuronal cells |
| 02/28/2012 | CA2289652C Methods of enhancing functioning of the upper gastrointestinal tract |
| 02/28/2012 | CA2219361C Human antibodies derived from immunized xenomice |
| 02/23/2012 | WO2012024452A2 Modified relaxin polypeptides and their uses |
| 02/23/2012 | WO2012024260A2 Intranasal delivery of cell permeant therapeutics |
| 02/23/2012 | WO2012024236A1 LTβR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS |
| 02/23/2012 | WO2012024223A2 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| 02/23/2012 | WO2012024196A2 A novel method for creating, suspending and stabilizing electronically modified reaction intermideates |
| 02/23/2012 | WO2012023955A1 Phospholipid depot |
| 02/23/2012 | WO2012023838A2 Fusion protein having transcription factor transactivation-regulating domain and protein transduction domain, and transcription factor function inhibitor comprising the same |
| 02/23/2012 | WO2012023811A2 Pharmaceutical composition for suppressing angiogenesis, and method for screening active material for suppressing angiogenesis |
| 02/23/2012 | WO2012023631A1 Pharmaceutical composition for inhibiting proliferation of cancer cells which comprises heat shock protein (hsp) and eci301 polypeptide, and cancer treatment method using same |
| 02/23/2012 | WO2012023623A2 Agent for treatment of hunter syndrome |
| 02/23/2012 | WO2012023588A1 Diagnostic marker for malignant melanoma, pharmaceutical composition containing substance suppressing function of histatin-1 protein, and immunosuppressive agent |
| 02/23/2012 | WO2012023290A1 Rasef as tumor marker and therapeutic target for cancer |
| 02/23/2012 | WO2012023284A1 Lhx4 as a target gene for cancer therapy and diagnosis |
| 02/23/2012 | WO2012023113A2 Designer osteogenic proteins |
| 02/23/2012 | WO2012022939A1 Treatment |
| 02/23/2012 | WO2012022740A1 Combination treatment of multiple sclerosis |
| 02/23/2012 | WO2012022040A1 Hiv-1 virus membrane fusion inhibitor and use thereof |
| 02/23/2012 | WO2012021964A1 Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (dcir) activity and signaling events |
| 02/23/2012 | WO2012021942A1 Tam receptors and tam receptor ligands in detection and modulation of neuropathological disease |
| 02/23/2012 | WO2012021922A1 Particulate substances comprising ceramic particles for delivery of biomolecules |
| 02/23/2012 | WO2011139738A9 Therapies using zanolimumab to enhance the immune response |
| 02/23/2012 | WO2011139488A3 Methods and materials for reducing cardiac xenograft rejection |
| 02/23/2012 | WO2011123683A3 Protease activated cytokines |
| 02/23/2012 | WO2011115447A3 C-terminal truncated peroxiredoxin-ii, and composition for preventing and treating apoptosis containing same |
| 02/23/2012 | WO2011106674A3 Use of endogenous antioxidant proteins in the treatment of stroke |
| 02/23/2012 | WO2011097181A3 Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders |
| 02/23/2012 | WO2003008563A3 Improved cytochrome p450 oxygenases |
| 02/23/2012 | US20120046638 Method of inducing a CTL response |
| 02/23/2012 | US20120046591 Treatment devices and methods with extending elements |
| 02/23/2012 | US20120046586 Skin treatment devices and methods with pre-stressed configurations |
| 02/23/2012 | US20120046519 Method and composition for synchronizing time of insemination |
| 02/23/2012 | US20120046441 Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery |
| 02/23/2012 | US20120046422 Multi-Arm Block Copolymers as Drug Delivery Vehicles |
| 02/23/2012 | US20120046240 Method of Producing Hydroxyalkyl Starch Derivatives |
| 02/23/2012 | US20120046236 Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| 02/23/2012 | US20120046235 Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation |
| 02/23/2012 | US20120046234 Therapeutic compounds |
| 02/23/2012 | US20120046233 Mutations in the lnk gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies |
| 02/23/2012 | US20120046232 Compositions and methods for reducing relapse of addictive behavior |
| 02/23/2012 | US20120046231 Composition and process for synthesizing polymerized human serum albumin for applications in transfusion medicine |
| 02/23/2012 | US20120046230 Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor |
| 02/23/2012 | US20120046229 Modified relaxin polypeptides and their uses |
| 02/23/2012 | US20120046228 Methods for Modulating Ovulation |
| 02/23/2012 | US20120046227 Designer osteogenic proteins |
| 02/23/2012 | US20120046226 Combined Treatment of Multiple Sclerosis |
| 02/23/2012 | US20120046225 Stable glucagon formulations for the treatment of hypoglycemia |
| 02/23/2012 | US20120046224 Treatment of diabetes and metabolic syndrome |
| 02/23/2012 | US20120046223 Exogenously triggered controlled release materials and uses thereof |
| 02/23/2012 | US20120046222 N-terminus conformationally constrained glp-1 receptor agonist compounds |
| 02/23/2012 | US20120046221 Albumin fusion proteins |
| 02/23/2012 | US20120046220 Phospholipid depot |
| 02/23/2012 | US20120046219 Melanocortin receptor-specific peptides |
| 02/23/2012 | US20120046218 Glycosaminoglycan-antagonising mcp-i mutants and methods of using same |
| 02/23/2012 | US20120046217 TNF-alpha Antagonists Containing IGFBP5 |